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With the increased international focus on personalized health care and preventive medicine, next-generation sequencing (NGS)
has substantially expanded the options for carrier screening of serious, recessively inherited diseases. NGS screening tests not
only offer reproductive options not previously available to couples, but they may also ultimately reduce the number of children
born with devastating disorders. To date, preconception carrier screening (PCS) has largely targeted single diseases such as
cystic ﬁbrosis, but NGS allows the testing of many genes or diseases simultaneously. We have developed an expanded NGS PCS
test for couples; simultaneously it covers 50 very serious, early-onset, autosomal recessive diseases that are untreatable. This is
the ﬁrst, noncommercial, population-based, expanded PCS test to be offered prospectively to couples in a health-care setting in
Europe. So far, little is known about how potential users view such a PCS test. We therefore performed an online survey in 2014
among 500 people from the target population in the Netherlands. We enquired about their intention to take an expanded PCS
test if one was offered, and through which provider they would like to see it offered. One-third of the respondents said they
would take such a test were it to be offered. The majority (44%) preferred the test to be offered via their general practitioner
(GP) and 58% would be willing to pay for the test, with a median cost of €75. Our next step is to perform an implementation
study in which this PCS test will be provided via selected GPs in the Northern Netherlands.
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INTRODUCTION
Preconception carrier screening (PCS) can detect whether a particular
couple has an increased risk of having a child with a certain
monogenic disease by testing the DNA of both partners to see
whether they are (asymptomatic) carriers of such a condition. Serious
autosomal recessive (AR) conditions with early onset impose a heavy
physical and psychological burden on the affected child and his or her
parents and are associated with high health-care costs. Such serious AR
conditions account for ∼ 20% of infant mortality and 10% of pediatric
hospitalizations.1,2
As information regarding carrier status is usually not available in a
family beforehand, the birth of a child with a serious AR condition
usually arises unexpectedly. Population-based PCS, irrespective of
family history or maternal age, can identify carrier couples so that they
can take this information into account in their family planning. The
key aim of offering a PCS test therefore is to increase reproductive
autonomy, although reduction of health-care costs might well be a
secondary result. As these reproductive choices can be made before the
onset of pregnancy, couples are faced with fewer time constraints and
less emotional stress compared with testing during pregnancy.3,4
Moreover, couples who learn about their risks before conception have
more reproductive options available to them than those whose risk is
detected during pregnancy or after the birth of an affected child and
they have more time to discuss these options.5 Carrier couples could,
for example, choose to make use of IVF with embryo selection (PGD)
or prenatal diagnostics.6,7 Other options include the use of a gamete
donor, adoption or refraining from having children with this partner.8
To date, PCS offered in European health-care systems usually tests
for one or a few conditions based on ancestry, such as Ashkenazi
Jewish founder variants, like Tay Sachs disease,9,10 and diseases with a
high prevalence in European populations, like cystic ﬁbrosis
(CF).6,11,12 The recent introduction of next-generation sequencing
(NGS) has allowed the screening of many genes or conditions
simultaneously,8,13,14 and the costs of this type of screening are
decreasing rapidly.12,15 This development has made it possible not
only to offer PCS to high-risk groups, but also to screen the general
population for a broad spectrum of conditions.
Such general population testing for several conditions simulta-
neously has not yet been offered within a health-care setting
in Europe. There are commercial screening tests, such as the American
Counsyl test16 that is available online and offered in Europe via the
Belgium ﬁrm Gendia. These commercial tests do not distinguish
between serious and mild conditions, or between early-onset and
late-onset conditions, so that arguably their clinical utility and
relevance in reproductive planning are less clear.17–19 In addition,
commercial tests are usually not offered preconception but during
pregnancy that also reduces the available reproductive options.12
Finally, pre- and post-test counselling is not always provided, so that
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a core element of good clinical practice, reaching well-considered
decisions, is not necessarily incorporated in the process.5
We developed an expanded NGS PCS test aimed at all couples
wishing to have a child. It involves a blood sample (10 ml per person)
and screens for ∼ 70 genes associated with some 50 very serious,
untreatable, early-onset, AR diseases simultaneously. Disease severity
was an important criterion for the composition of our panel.
We included only those conditions that can be characterized as very
serious, that is, early-onset conditions that involve severe mental
and/or physical retardation, severe pain and/or premature death.
Moreover, as the availability of treatment is regarded as an important
characteristic in the classiﬁcation of disease severity,20 we also chose
to include only conditions that can be characterized as untreatable.
For this reason, conditions included in the Dutch newborn screening
programme and classiﬁed as treatable, such as CF, have not been
included in our panel, despite them being serious and early onset.
Based on our selection criteria, literature review2,8,13,20,21 and discus-
sions with clinical geneticists, pediatricians, specialists in pediatric
metabolic disorders and ethicists, we established a ﬁnal ﬁrst test panel
(see Supplementary Materials).
The PCS test analysis has been validated in silico by the Department
of Genetics’ Genome Diagnostics section using whole genome
sequencing data from the Genome of the Netherlands (GoNL).22
On the basis of the PCS gene list and both average allele frequencies
and the PCS disease prevalence information, we used the Hardy–
Weinberg equilibrium model to calculate a carrier risk of 1 in 150 for
variants leading to the same serious disease per couple. Using the
GoNL exome sequencing data set, an in silico proof-of-principle study
was conducted to examine 100 randomly chosen males and 100
females, creating 100 randomly chosen couples. The variants asso-
ciated with the genes included in the PCS panel were compared with
the relevant ‘damaging’ variants in the Human Gene Mutation
Database (HGMD).23 Other deleterious variants (premature loss or
gain of termination codons, shifts in the reading frame and consensus
splice site changes) not currently present in the HGMD were also
examined. Of the 100 randomly paired couples tested for the proof-of-
principle GoNL test, we found no carrier couples for a serious,
recessively inherited disease, as could be expected with a carrier risk of
1 in 150. We did ﬁnd, on average, 0.69 frame shift/premature stop
codon/splice site/HGMD variants per person. Although six individuals
were found to carry variants within the same gene as their partner,
these variants were not pathogenic in both, and hence the couples
were not at risk of having children with the diseases associated with
these genes. The couples were thus not deemed to be a carrier couple.
In contrast to other PCS tests, the current test is offered and
analysed per couple and not per individual, meaning that each couple
receives a result based on their combined genetic information.
Important argument for offering couple results only is that a couple
result provides prospective parents with information about their
chance of having a child with a serious hereditary disease, whereas
individual carrier results do not.
Diagnostic analysis parameters have been adjusted to ensure that
only causal recessive variants are reported and that secondary ﬁndings
not applicable to the couples’ carrier status are avoided. Both known
deleterious variants listed in the HGMD as well as other variants
predicted to truncate and affect gene expression are considered and
reported. Couples are considered as screen-positive only if disease-
relevant sequence variants are found in the same gene in both
individuals, as only in this case is their risk of having a child with
the associated disease increased.
The current PCS test will detect an increased risk in ∼ 1 in 150
couples. Such a couple will have a 1 in 4 (25%) chance per pregnancy
of having a child affected by the condition that both the parents carry.
Therefore, for each couple in the population, the average risk of
conceiving a child with one of the conditions in our panel is 1 in 600
per pregnancy (1 in 150 times 1 in 4). This is higher than the birth
prevalence of children with Down syndrome (1 in 1000) or CF (1 in
2500 to 1 in 3500) in Europe,6,24,25 conditions for which screening is
widely accepted or even recommended.
We want to investigate whether responsible implementation of this
population-based expanded NGS PCS test is desirable and feasible in
Dutch health care. As a ﬁrst step, we investigated in the current study
potential users’ intentions to undertake the test and through which
provider they would like to see it offered.
MATERIALS AND METHODS
Sample and target population
Potential participants, both men and women with a partner and in the
reproductive age, were recruited online by a survey research sampling company
(Survey Sampling International, SSI; http://www.surveysampling.com) in
March 2014. SSI panel participants were invited to participate in our survey
and sampling was stratiﬁed according to gender, educational level and
geographical region in order for the sample to be representative for the Dutch
population. Only participants who met all our inclusion criteria, were aged
18–40 years, had a partner and were living in the Netherlands were given access
to our online questionnaire. SSI panel participants were invited until 500
respondents were included. To award the time respondents invested in
participating in the study, SSI offered an incentive (in reward points up to a
maximum value of € 2.50) to the respondents. Ethical clearance was granted by
the Medical Ethical Review Committee of the University Medical Center
Groningen (M14.152635).
Survey design
The survey was developed by a multidisciplinary research team and aimed to
measure the intentions of potential users as well as their ‘supply’ preferences.
An explorative qualitative interview study preceded the development of the
survey. The qualitative interview study involved 20 potential users (11 female
and 9 male, aged 18–28 years) and made use of a semistructured approach that
was tested in a prepilot with 3 potential users. In the interviews we explored
which factors inﬂuenced people’s intention to participate in PCS and people’s
provider preferences. The interviews showed that the following factors were
found to be of importance for people’s intention: the opinion of partner, family
and friends; fear for a positive test result; being familiar with hereditary diseases;
people’s attitude towards quality of life for future child and parents; the
involvement of a professional; and the costs of the test. With regard to provider
preferences, we found that it was considered important that information about
the test was offered online and that information brochures were available and
present at locations where people often go to when thinking about having
children, such as general practitioners (GPs), hospitals and midwives. Finally,
almost all respondents indicated wanting to discuss the option of testing with a
professional during a personal encounter. The interview study provided us with
important input for the development of our questionnaire, among others for
the measurement of supply preferences for which no standardized measure-
ments were available. For the measurement of intention we also made use of
the Theory of Planned Behaviour Framework26 and previous research on CF
screening.27,28
The survey started by providing respondents with (written) background
information about population-based PCS. This outlined how everyone is likely
to carry one or more AR variants that cause no problems or symptoms for that
individual. However, if both partners carry such a variant in the same gene, the
couple has a 1 in 4 (25%) chance of an affected child in each pregnancy.
Respondents were told that the PCS test would screen for a large set of very
serious, early-onset diseases that cannot be treated. No information was given
about the chances of being a ‘carrier couple’, because we wanted to assess
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respondents’ perceived risk of this. The survey was created in Dutch using
Unipark (www.unipark.de).
Measures
Intentions for population-based PCS. Potential users’ intentions to take up
population-based PCS were measured by two items: whether they intended to
take up the current PCS test and their interest in other forms of population-
based PCS. Intention was measured according to the Theory of Planned
Behaviour framework.26 The intention to take up the PCS test, if it were
offered, was measured with one item (if this preconception carrier screening
test were to be offered, I would be willing to participate) and rated on a 7-point
Likert scale with anchors likely (1) and unlikely (7). The scores were categorized
as ‘likely’ (scores 1–2), ‘undecided’ (3–5) and ‘unlikely’ (6–7).
In addition, we presented the respondents with 8 arguments in favour and
10 arguments against taking a PCS test and asked respondents what they
perceived as most important. The arguments were developed within our
multidisciplinary research team and tried to address a wide variety of possible
(ethical) pro and contra arguments for PCS testing. Examples of pro arguments
were ‘I want to spare any child a life with a serious hereditary disease’ and
‘I want to be able to prepare myself for having a child with a serious hereditary
disease’, whereas contra arguments included ‘I do not want to know if my
partner and I are carriers’ and ‘I am against the selection of children by genetic
screening’ (see Table 2).
Finally, we wanted to reach a better understanding of the spectrum of
conditions respondents would like to be screened for, in addition to the
untreatable and early-onset diseases speciﬁed in our test. We drew up new
items to measure their interest in different types of PCS tests. We asked
respondents to rate their interest in four types of PCS tests: the current test
screening for very serious, early-onset, untreatable conditions; a test screening
for very serious, but to some extent treatable conditions; a test screening for
very serious conditions that have an onset later in life; and a test screening for
nonhealth-related predispositions for athletic ability or musicality, for example.
Respondents were asked to indicate how much they would be interested in
these different forms of population-based PCS tests on a 5-point Likert scale
with anchors interested (1) and not interested (5). The scores were reduced to
‘interested’ (score 1, 2), ‘neutral’ (3) and ‘not-interested’ (4, 5).
Preferences on the provision of the PCS test
We measured respondents’ preferences regarding the provision of the PCS test
with the following newly constructed items. We asked respondents: (1) whether
they have objections to provision of the PCS test to couples only; (2) to indicate
their preferred provider from a list of possible providers (eg, GP, gynaecologist,
pharmacist, direct to consumer); (3) to indicate from a list how they would like
to be informed about the PCS test (general information (via brochure or
website) or individual information (via e-mail, telephone or face-to-face in a
pre-test counselling session); and (4) whether they would be willing to pay for
the PCS test, and if so, the maximum amount they would be willing to pay.
Data analysis
Analyses were performed using IBM SPSS version 22 (IBM Corp., Armonk,
NY, USA). Descriptive analyses were used to describe the sociodemographic
characteristics of the respondents, their intentions for taking up the PCS test
and their provider preferences. Educational level was categorized, in accordance
with the classiﬁcation of Statistics Netherlands, as: ‘low’ (ﬁnished primary
school, lower secondary school or vocational training); ‘intermediate’ (higher
level secondary school or intermediate vocational training); and ‘high’ (higher
vocational training or university). Age was divided into three groups: 18–24,
25–32 and 33–40 years. Fisher’s exact tests were used to compare nominal or




In our study, 869 individuals met the inclusion criteria and received
access to our questionnaire. Of these, 504 (58%) respondents
completed the survey. There were no differences seen in gender when
comparing dropouts with respondents. Dropouts were, however,
a little older (average and median age of 31 years compared with an
average age of 29 years and a median age of 28 years for respondents)
and less often planned to have children (59% compared with 70% for
respondents). Respondents’ characteristics are presented in Table 1.
Of the 504 respondents, 72% were female. The mean age was 29
Table 1 Sociodemographic characteristics of respondents by intention group
All, 504 (100%) Unlikely, 74 (100%) Undecided, 257 (100%) Likely, 171 (100%) P-value
Gender 0.099
Female 364 (72%) 49 (66%) 180 (70%) 133 (78%)
Male 140 (28%) 25 (34%) 77 (30%) 38 (22%)
Age (in years) 0.040
18–24 161 (32%) 18 (24%) 98 (38%) 44 (26%)
25–32 177 (35%) 27 (37%) 85 (33%) 65 (38%)
33–40 166 (33%) 29 (39%) 74 (29%) 62 (36%)
Educational level 0.601
Low 63 (13%) 12 (16%) 32 (12%) 18 (10%)
Intermediate 269 (53%) 36 (49%) 143 (56%) 90 (53%)
High 172 (34%) 26 (35%) 82 (32%) 63 (37%)
Marital status (duration of relationship) 0.349
Not living together (2 months–9.5 years) 104 (21%) 16 (22%) 55 (21%) 33 (19%)
Living together (7 months–11 years) 234 (46%) 27 (36%) 124 (48%) 82 (48%)
Married/registered partners (18 months–25 years) 166 (33%) 31 (42%) 78 (30%) 56 (33%)
Religion o0.001
No 329 (65%) 30 (40%) 175 (68%) 123 (72%)
Yes 175 (35%) 44 (60%) 82 (32%) 48 (28%)
Wish to have child 0.080
Yes 351 (70%) 44 (59%) 182 (71%) 124 (73%)
No 126 (25%) 27 (37%) 57 (22%) 41 (24%)
Already pregnant 27 (5%) 3 (4%) 18 (7%) 6 (3%)
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(SD 6.19) years and the median age was 28 years. Of the participants,
34% had a high education level, 53% an intermediate level and 13%
a lower level. Relationship durations ranged from 2 months to 25
years. The majority of the respondents (65%) were not religious.
Finally, 70% of the respondents expressed the desire to have children
with their current partner, 25% did not wish to have a child and 5%
were already pregnant.
Respondents’ intention to undertake PCS
With regard to respondents’ intention to undertake PCS, we ﬁnd that
34% would take the test if it were offered, 15% would be unlikely to
take the test and 51% were still undecided. In Table 1, the response
patterns between the different sociodemographic groups are presented
per intention group (unlikely, undecided, likely). Signiﬁcant differ-
ences were observed for both age and religion. Especially, young
people reported more often to be undecided about testing: the
proportion of young people was signiﬁcantly higher in the ‘undecided’
group than the other intention groups. We also found that signiﬁ-
cantly more religious respondents were in the ‘unlikely’ group,
indicating an inverse relationship between religion and intention to
take the test.
We further asked about their arguments pro and contra PCS testing.
Table 2 displays which of the 8 presented pro and 10 presented contra
arguments for PCS testing are perceived as being most important. For
the sample as whole, the argument that people want to spare their
child a life with a serious hereditary disease is the pro argument
mentioned most often by respondents (39%) as being most important.
Being able to prepare for having a child with a serious hereditary
disease was the second most important pro argument, mentioned by
14%, and avoiding abortion was brought forward by 10%. The most
important contra argument (for 23% of respondents) was that
respondents just did not want to be bothered by knowing whether
they were an at-risk couple, whereas 13% said they were afraid that
being a carrier would have consequences for their relationship, and
12% were against selection of children by screening.
Table 2 also displays per intention group which pro and contra
arguments were perceived as most important. The most often selected
pro argument, namely to spare their child a life with serious hereditary
disease, was put forward particularly by those who were likely to take
the test or undecided (45% and 41% versus 23% for the unlikely
intention group). The intention groups also differed with regard to
some of the contra arguments they perceived as being most important.
In the ‘unlikely’ group, 38% said their most important contra
argument was that they were against selecting children by screening
(against 4% in the likely group). In contrast, in the ‘likely’ group, 16%
said the most important contra argument was being afraid that ﬁnding
out being a carrier couple might have consequences for their
relationship (against 1% in the unlikely intention group).
We ﬁnally measured the interest for other diseases and predisposi-
tions to be included in a PCS test. Figure 1 shows that respondents’
interest in the different PCS tests was very similar, except for screening
for nonhealth-related predispositions. Of all the respondents, 56% were
interested in the current PCS test for serious, untreatable and early-
onset disorders, 55% were interested in tests that screen for very serious
but to some extent treatable conditions and 54% were interested in tests
that screen for late-onset conditions. In addition,19% were interested in
tests that screen for nonhealth-related predispositions.
Preferences on the provision of the PCS test
With regard to providing the PCS test, we ﬁrst asked whether










I think that my partner and I as (future) parents have a responsibility to do this test. 49 (10%) 6 (8%) 20 (8%) 22 (13%)
I want to spare our child a life with a severe hereditary disease. 199 (39%) 17 (23%) 104 (41%) 77 (45%)
Carrier testing is socially expected from me and my partner. 14 (3%) 1 (1%) 12 (5%) 1 (1%)
If the test shows that we together are not carriers, this would be a great relief. 35 (7%) 4 (6%) 21 (8%) 10 (6%)
I want to prevent my partner and I having to take care of a child with a severe hereditary disease. 32 (6%) 1 (1%) 16 (6%) 15 (9%)
I want to know in good time if our child is at risk so as not to be confronted by having to make a
choice about a late abortion.
44 (9%) 5 (7%) 18 (7%) 21 (12%)
I want to be able to prepare myself for having a child with a severe hereditary disease. 71 (14%) 21 (28%) 37 (14%) 13 (7%)
I think that abortion should be prevented if possible. 50 (10%) 17 (23%) 24 (9%) 9 (5%)
Other pro arguments (eg, we are not capable of taking care of a child with a severe hereditary
disease).
10 (2%) 2 (3%) 5 (2%) 3 (2%)
Arguments contra testing
I do not want to know if my partner and I are carriersmacmac 114 (23%) 22 (30%) 66 (26%) 26 (15%)
I am against selecting children by screening (such as in this test). 63 (12%) 28 (38%) 28 (11%) 7 (4%)
I am afraid that if we turn out to be carriers this will have consequences for my relationship. 65 (13%) 1 (1%) 36 (14%) 27 (16%)
I am afraid that if we turn out to be carriers this will have consequences for my insurance policies. 23 (5%) 1 (1%) 11 (4%) 11 (6%)
I am afraid that if we turn out to be carriers we will be regarded as people with a disease. 18 (4%) 1 (1%) 11 (4%) 6 (4%)
I am afraid that if we turn out to be carriers this will be registered with the authorities. 20 (4%) 1 (1%) 7 (3%) 11 (6%)
I am afraid that if we turn out to be carriers we will end up in a medical treadmill. 49 (10%) 2 (3%) 24 (9%) 23 (13%)
The test result will have no inﬂuence on my having children with my partner. 56 (11%) 9 (12%) 23 (9%) 24 (14%)
A test would take away the romance of a pregnancy. 22 (4%) 1 (1%) 15 (6%) 6 (4%)
By taking a test, becoming pregnant is no longer natural. 27 (5%) 4 (6%) 17 (7%) 6 (4%)
Other contra arguments (eg, if my partner does not want to be tested). 47 (9%) 4 (6%) 19 (7%) 24 (14%)
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respondents object to provision of the test to couples only and not on
individual basis. The majority (70%) did not object to the provision
of a couple-based test, 15% did object and 15% were undecided.
We then asked respondents to indicate which provider they preferred
from a list of possible providers. Their preferences are shown in
Figure 2. The majority (44%) preferred the PCS test to be offered via
the GP and this preference was not related to respondents’ intentions.
There was no clear, second-best alternative. Almost 20% did not state
a preference at all and only 3% showed an interest in a direct-to-
consumer test.
We also enquired about preferences for information about the PCS
test and whether respondents would prefer a consultation with
a health-care professional via e-mail, telephone or face-to-face
counselling. Figure 3 shows that most respondents prefer individua-
lised information via face-to-face consultation: 37% preferred this
information route. General information by means of a brochure was
also regarded as important and was the preferred option for 21% of
respondents; 15% stated no preference.
Finally, we asked whether respondents would be willing to pay for
the PCS test, and if so, what their maximum amount would be. Of
those who said they would likely take the test if it was offered, 58%
would be willing to pay for it. The maximum amount ranged from €5
up to €5000, with a median amount of €75.
DISCUSSION
We have developed an NGS PCS test aimed at couples who
want to have children: it simultaneously covers ∼ 70 genes
associated with some 50 very serious, early-onset and untreatable
AR diseases (see Supplementary Materials). This is the ﬁrst
noncommercial, population-based PCS test to be offered to
prospective couples in a health-care setting in Europe. Our results,
therefore, present a ﬁrst glimpse of how potential users view such a
PCS test.
Our study reveals a clear positive attitude towards this form of
population-based PCS: more than half (56%) of the respondents
were interested in the test and one-third said they intended to
take the test if it were offered. A minority (15%) were unlikely
to take the test, but many respondents (51%) were still undecided
after receiving this ﬁrst information about the PCS test. A higher
proportion of younger respondents were undecided. Respondents
also reported an interest in testing for serious but later-onset
diseases and in diseases that are to some extent treatable. There
was less interest in testing for nonhealth-related predispositions
(eg, athletic ability), although almost 20% were interested in such
testing. Different arguments pro and contra testing were reported.
The most important pro argument (for 39% of the respondents)
was to be able to spare a child a life with a serious hereditary
disease, followed by being able to prepare for having a child with
a serious hereditary disease (14%). Remarkably, the pro argument
of sparing oneself of having to take care of a severely affected child
was mentioned far less often (6%). The contra argument perceived
as most important was that people did not want to be bothered
by the knowledge of being a carrier couple. The arguments pro
and contra varied slightly between the groups intending to
undertake the test or not. Those who were unlikely to take
the test were more against screening and against abortion, whereas
those who were likely to take the test had more diverse arguments
that were often related to their relationship. Finally, we found
that the GP was the preferred provider of the PCS test. Given the
Dutch health-care context, which has a strong primary care
structure29 and in which healthy young women are not regularly
seen by a gynaecologist but primarily by their GP (who plays
an important role as a gatekeeper), this preference is perhaps
not surprising.
The sample of 500 respondents was chosen to represent Dutch
potential users of the PCS test. Although the sample selection was
performed with great care, we do not know how representative our
sample was for Dutch users of the PCS test. Female respondents were
overrepresented that may have inﬂuenced our ﬁndings, although we
observed no differences between the sexes. Furthermore, nonresponse
bias is difﬁcult to assess in online samples. People who do not have
access to the internet are excluded, for example, and only those who
choose to join a research panel can be included. Furthermore,
response rates for samples can be accurately reported when
the sampling frame is known in advance. However, in internet
surveys the sampling frame is often unknown in advance and response
rates become meaningless.30 The best parameter that can be provided
Figure 1 Interest in differently composed population-based PCS tests.
Figure 2 Preferences for different providers of the PCS test.
Figure 3 Preferences for different forms of information about the PCS test.
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is a ‘participant rate’ that was 58% is our study. Despite the sampling
problems, we believe they give a good indication of the views
of potential Dutch users of the PCS test. Further research will be
necessary to validate our results and to investigate intentions
and provider preferences in other populations with different health-
care systems.
As our test will be the ﬁrst noncommercial, population-based,
expanded PCS test to be offered prospectively to couples in a health-
care setting in Europe, little was known about how potential users
would view such a test and how our results would relate to other
research. The differences we found in arguments pro and contra
between different intention groups relate to results from Schneider
et al,31 who recently explored preconception genomic carrier screening
in a focus group study and found that people displaying a ‘certain’
versus a ‘hesitant’ orientation towards preconception genomic carrier
screening, demonstrate differences in perceived advantages or dis-
advantages of screening. Moreover, extensive research results are
available regarding the offer of PCS tests for single AR conditions,
especially on testing for CF. This research has shown that 54–80% of
the general population is interested in carrier screening for CF:32 56%
would take the test, 27% were undecided and 17% would not be
willing to participate.28 Important reasons for participating in CF
screening were to avoid having a child with CF and to prepare for a
child with CF, whereas the main reasons for not participating included
lack of time and not wanting to know the test results.33 Finally, the GP
was in the CF research also found the preferred delivery route.32,34
Given that prospective users in both our research and the research
on CF had a positive attitude towards the potential implementation of
an expanded carrier test, we have decided to proceed to the next step
that is to start an implementation study with the test being offered to
couples from the general population. Our ﬁndings have provided
important input for the design of such an implementation study. Our
goal will be to investigate whether our PCS test can be implemented
responsibly via GPs as part of preconception care for couples wishing to
have a child. The responsible implementation of the test will be evaluated
by studying the psychological impact, uptake and practical feasibility.
An expanded PCS test for the general population that screens for
several conditions simultaneously is currently not being offered within
a health-care setting in Europe. As a result, a child born with a serious
AR condition is not anticipated in most cases. With the offer of
population-based PCS, carrier couples can be identiﬁed preconception
and they can then incorporate this information in their family
planning. Our NGS PCS test is aimed at all couples wishing to have
a child; simultaneously it covers ∼ 70 genes associated with some 50
very serious, AR diseases. One-third of our respondents said they
would take this test if it were offered. They would prefer it to be
offered via their GP and after face-to-face pretest consultation. Many
would be willing to pay for the test (58%) with a median cost of €75.
These ﬁndings have been incorporated into our study to investigate
whether responsible implementation of population-based expanded
carrier screening in health care is possible and desirable.
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